Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Parkinson’s Disease Burden by Hoehn and Yahr Stage Using Real-World Data From the Parkinson’s Outcomes Project
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
150

To describe the patient burden of moderate-to-advanced Parkinson’s disease (PD) stratified by Hoehn and Yahr (H&Y) stage.

There is limited literature describing the burden of moderate-to-advanced PD. We used data from The Parkinson’s Foundation Parkinson’s Outcomes Project (PF-POP) to assess the relationship of H&Y stage to subjective and objective measures of disease burden.

We analyzed data from patients in the PF-POP with at least 3 years of post-index follow-up who met the following criteria: living in the US; >90% certainty of idiopathic PD; PD diagnosis for ≥5 years at index date; and H&Y stage 2 or greater off medication at index date. All data are reported at index.

1181 patients met study criteria: 67% were male and 93% were White. Mean age was 65 years and mean time since PD diagnosis was 10 years; the majority were classified as H&Y stage 2 (56%) or 3 (39%), with 5% stage 4. Mean PDQ-39 Summary Index (quality of life assessment) score was 5.1 overall and 4.1, 6.0, and 8.9 for H&Y stage 2, 3, or 4, respectively. Patients reporting any falls in the prior 3 months (43% overall; 26%, 62%, and 80% for H&Y 2, 3, or 4, respectively) and the number of hospital visits (0.29 overall and 0.23, 0.32, 0.59, respectively) and emergency room visits (0.33 overall and 0.27, 0.38, 0.79, respectively) in the prior 12 months also appeared to increase with H&Y stage.

At index, both subjective and objective measures of patient burden appeared to increase with more advanced H&Y stage in patients with moderate-to-advanced PD. It will be important to understand how these measures track over time in this patient population.
Authors/Disclosures
Elisabeth Fine, PhD
PRESENTER
Elisabeth Fine, PhD has received personal compensation for serving as an employee of Voyager Therapeutics, Inc. Elisabeth Fine, PhD has received stock or an ownership interest from Voyager Therapeutics.
No disclosure on file
No disclosure on file
Mark C. Stahl, MD, PhD (Insmed Gene Therapies) Dr. Stahl has received personal compensation for serving as an employee of Avidity Biosciences. Dr. Stahl has stock in Avidity Biosciences.
No disclosure on file